Doug Drysdale retweeted
Biopharma M&A - Great slides from Lifesci Capital. Slow activity in Q3 but still 2026 is trending towards being a record year.
Doug Drysdale retweeted
An open letter from the Chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi
worldpharmanews.com/business…
Doug Drysdale retweeted
Biotech is a stock pickers market right now. So many wonderful companies are beaten down 40% or more from their highs. You can go through chart after chart of high quality late stage and early commercial companies and find great value. On the other side, there is a AI theme in biotech driving a massive bubble in many of the techbio companies. Same narrative that existed in 2021 before they all imploded.
If you avoid the bubbly biotech stocks and focus on the mispriced excellence, there is a lot to love in biotech. I have at least 10 companies I love and want to build positions into. Then there are at least 5 to 10 more I like but don't even own. Be a wise investor and avoid the meme garbage stocks and focus on the undervalued excellence.
Doug Drysdale retweeted
By systematically stripping down the complex structure of the LSD molecule, scientists have pinpointed the exact components that trigger hallucinations. This breakthrough paves the way for safer, non-hallucinogenic psychiatric treatments that harness the… dlvr.it/TVf2bn
Doug Drysdale retweeted
from heidi overton's opening remarks in her confirmation hearing: "President Trump's direction for me in this role should I be confirmed is to go fast. Slow and prohibitive requirements for cutting-edge therapies at the FDA means investment is increasingly flowing to China, who has found ways to do things faster and cheaper... China has surpassed the United States as a top venue for clinical trials... When we lose this advantage, we lose our health security. And when we lose our health security, we lose everything." "The FDA has begun work... to make sure every aspect of clinical trials and drug development is optimized." "The recent rapid approval of a new treatment for pancreatic cancer... should be the norm for the FDA."
Doug Drysdale retweeted
Link to full paper:
journals.sagepub.com/doi/10.…
Disclosure: long $BETRF
Replying to @insidepharma
4/7
Is there any human signal?
Yes.
Karst et al. (Cephalalgia, 2010) tested racemic 2-Br-LSD (BOL-148) in a small pilot in cluster headache. Authors reported reduced attack frequency/intensity, without hallucinations in that study, after just 3 doses - lasting for 4 months.
That is historical, racemic mix data. BETR-001 is the selected active stereoisomer. Different molecule package; same chemical family.
Doug Drysdale retweeted
Claude has discovered a previously unknown enzyme system hidden in the DNA of bacteriophages. Beside the enzyme’s gene sits a long array of repeating DNA—a structure that looks somewhat similar to CRISPR.
We don’t yet understand what this system does, but only a handful of known systems share its features, and all of them are able to cut, copy, and paste DNA. Historically, the discovery of such programmable systems has helped revolutionize medicine. CRISPR, for instance, is now the foundation of genetic medicines. But it will take much more work to learn what this system does, and whether it can be put to similar use.
Read more: anthropic.com/news/claude-di…
Doug Drysdale retweeted
“The financing was led by Deep Track Capital with significant co-investments from Coastlands Capital, Marshall Wace, RA Capital Management and Perceptive Advisors, and participation from Adage Capital Management, Affinity Asset Advisors, Kalehua Capital, Sphera Fund Management, Squadron Capital Management, Stonepine Capital Management, Woodline Partners LP and other healthcare specialized institutional investors.”
$BETRF
BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
$BETRF
finance.yahoo.com/healthcare…
Doug Drysdale retweeted
The psychedelic drug LSD eased anxiety in a late-stage trial, paving the way for a probable approval in the US within the next two years. Read more: newscientist.com/article/258…
Doug Drysdale retweeted
Discussion w the senior BD leaders at big pharma and one surprising point made is that more than one said that they are focused on earlier stage and are comfortable with clinical risk. They don’t seem to be shaken up by avidity/$NVS recent post deal setback. “In BD, risk is your friend. If you don’t take risk. You’ll pay what others think it’s worth” talking about transacting phase 2 or earlier, pre readout $XBI $IBB
Doug Drysdale retweeted
Breaking: Michael Burry says OpenAI and Anthropic are faking the AI warnings due to slow growth ahead of IPOs
Below are his reasonings:
1. LLMs are not AI and won't be AGI. There is nothing AI to slow down.
2. Competition is coming up fast, slowing benefits incumbents.
3. IPOs need hype & puffery; "we are so awesome it could become dangerous" is hype & puffery
4. Cover for real uncontrollable slowing growth as IPOs look to be pushed out
Doug Drysdale retweeted
Psychedelic medicine is entering a new phase.
In the latest WTR Healthcare Happenings podcast recap, Doug Drysdale explores commercialization, clinical progress, and the evolving investment landscape shaping the future of neuroscience.
Read Robert Sassoon's full recap report for more!
#Healthcare #Biotech #Neuroscience #Psychedelics #LifeSciences #Investing @insidepharma
Doug Drysdale retweeted
JUST IN: ChatGPT surfaces a crucial mutation in a woman’s old biopsy records, helping doctors determine her terminal glioblastoma diagnosis was incorrect.
Doug Drysdale retweeted
40+ million Americans live with migraines. One molecule. BetterLife Pharma is developing BETR-001. Multiple pathways. Still in development. (CSE: BETR / OTCQB: BETRF). Not investment advice.
Doug Drysdale retweeted
People who don't follow cancer research often ask me why we haven't cured cancer. That perception masks a wonderful reality: We make amazing, stepwise progress every year, and the result is that many people live much longer today than they would have previously.
Right now we're in the thick of the annual meeting of the American Society of Clinical Oncology, the biggest research meeting on new cancer medicines, and this morning a bunch of really important studies dropped. I'm going to review them here.
This first image is the result for daraxonrasib, a treatment for pancreatic cancer that is generating consdirable excitement. The green line is the probability of living for patients who got the new drug; the gray one is the chemo control group.
If you follow cancer drugs, a chart like this will make your breath hitch a little. I'm going to review these and some other data here.
Doug Drysdale retweeted
For millions of Americans, many treatments for mental illness never deliver relief. This is not acceptable.
@ARPA_H's EVIDENT initiative is awarding up to $139 million to accelerate the research, approval, and responsible access to breakthrough mental health treatments, including psychedelic therapies like ibogaine, to deliver real solutions for Americans with serious mental illness—especially our veterans.
Doug Drysdale retweeted
Today, we took long-overdue action to restore science, accountability, and the rule of law.
In September 2023, the Biden FDA pushed a number of peptides into Category 2 — “Bulk Drug Substances that Raise Significant Safety Risks” — driving a dangerous black market that puts Americans at risk.
Now, after nominators withdrew 12 peptides, the FDA will remove them from Category 2 and will bring them to PCAC at its next two meetings, beginning in July—where independent experts will rigorously evaluate each substance on its scientific merits using full clinical, pharmacological, and safety evidence.
• BPC-157
• Thymosin beta-4 fragment (LKKTETQ)
• Epitalon
• GHK-Cu (injectable)
• MOTS-c
• DSIP (Emideltide)
• Dihexa Acetate
• Ibutamoren Mesylate
• Melanotan II
• KPV
• Semax (heptapeptide)
• Cathelicidin LL-37
This action begins to restore regulated access and will immediately begin shifting demand away from the black market.
We will follow the science, enforce the law, and deliver the clarity patients, providers, and pharmacies deserve.
Doug Drysdale retweeted
This is exactly what we built.
Our genetics kit maps 111 DNA markers including 7 CYP enzymes that affect how you metabolize GLP-1s and 25+ other peptide compounds. CLIA-certified lab. $250.
The era of "one dose fits all" is ending. Your DNA determines your response.
The Wall Street Journal@WSJApr 8United States
United StatesConnected via WebAccount-level information, not a live location or per-post device.
A new study identified genetic variants that researchers say can affect pounds lost while taking a GLP-1 drug. on.wsj.com/4e9xcBO
Doug Drysdale retweeted
Everyone is covering Terafab as a chip factory.
It is not a chip factory.
Last night in Austin, Elon unveiled a facility that makes masks, fabricates chips, and tests them inside a single building with a nine-month recursive improvement cadence. No such loop exists anywhere else on Earth. Then he told you 80% of the output goes to space. Then he showed you a 100-kilowatt AI satellite with solar panels and radiators, scaling to megawatt range. Then he said Optimus plus photovoltaics will be the first von Neumann probe, a machine capable of replicating itself from raw materials found in space.
Nobody connected the sequence.
Terafab produces 1 terawatt per year of compute. The entire United States consumes 0.5 terawatts of electricity. Musk is building a single factory whose output in AI silicon exceeds twice the power consumption of the country it sits in. And he is sending 80% of it off-planet because Earth literally cannot power what he is building.
Follow the mechanism. Terafab seeds the chips. Starship launches Optimus robots and solar arrays at 100 million tons per year. The robots mine lunar and asteroid regolith for silicon, iron, and nickel. They 3D-print more robots. They fabricate more solar panels. They assemble more AI satellites. Each satellite runs hotter-burning D3 chips designed specifically for vacuum, where free radiative cooling eliminates the thermal constraints that strangle every terrestrial data center on the planet. The nodes replicate. The replication is exponential.
This is a Dyson Swarm bootstrap hidden inside a semiconductor announcement.
The math is public. The Sun outputs 3.828 times 10 to the 26th watts. A 2022 paper in Physica Scripta calculated that 5.5 billion satellites at 290 kilograms each, robotically manufactured from Mars resources, capture enough solar energy to meet all of Earth’s power needs within 50 years. A 2025 paper in Solar Energy Materials calculated a partial swarm capturing 4% of solar output yields 15.6 yottawatts, roughly a billion times current human civilization’s total energy budget. Musk just announced the factory that builds the chips that go inside the satellites that replicate themselves forever.
92% of advanced logic chips are fabricated in Taiwan. One factory in Austin does not fix that. But one self-replicating system seeded by that factory, launched by the only company with reusable heavy-lift rockets, assembled by the only humanoid robot in mass production, and powered by the only star within reach, does not fix a supply chain. It obsoletes the concept of supply chains entirely.
The market priced this as a $20 billion capex story about semiconductor independence.
The actual announcement was the engineering blueprint for Kardashev Type II.
Humanity sits at 0.73 on the Kardashev scale. 18 terawatts. The distance between here and harnessing a star is not a technology gap. It is a recursion gap. And recursion is exactly what a single building in Austin that makes its own masks, builds its own chips, tests its own chips, and launches the output into orbit on its own rockets was designed to close.
Every civilization that makes it past this point never looks back.































